

# François Chasset

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8416837/publications.pdf>

Version: 2024-02-01

58  
papers

1,382  
citations

448610

19  
h-index

425179

34  
g-index

64  
all docs

64  
docs citations

64  
times ranked

1587  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immediate consequences and solutions used to maintain medical education during the COVID-19 pandemic for residents and medical students: a restricted review. <i>Postgraduate Medical Journal</i> , 2022, 98, 380-388.	0.9	10
2	Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: A retrospective multicenter cohort study of 56 patients. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 203-206.	0.6	3
3	Acropulpsitis in systemic lupus erythematosus is associated with high type 1 interferon signature. <i>Experimental Dermatology</i> , 2022, 31, 819-820.	1.4	0
4	Clinical efficacy of selective JAK1 inhibition and transcriptome analysis of chronic discoid lupus erythematosus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	3
5	Serum interferon- $\lambda$ levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 901-903.	0.5	11
6	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2110730.	1.2	52
7	Prevalence and factors associated with long-term remission in cutaneous lupus: A longitudinal cohort study of 141 cases. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 323-332.	0.6	4
8	Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: A multicenter retrospective observational study of 40 patients. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1171-1174.	0.6	14
9	Characterization of drug-induced cutaneous lupus: Analysis of 1994 cases using the WHO pharmacovigilance database. <i>Autoimmunity Reviews</i> , 2021, 20, 102705.	2.5	7
10	Cutaneous Kikuchi disease-like inflammatory pattern without lymph node involvement is associated with systemic disease and severe features in lupus erythematosus: A case-control study. <i>Lupus</i> , 2021, 30, 473-477.	0.8	1
11	Echocardiographic features in antiphospholipid-negative Sneddon's syndrome and potential association with severity of neurological symptoms or recurrence of strokes: a longitudinal cohort study. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 119-128.	0.5	2
12	Expansion of Circulating CD49b+LAG3+ Type 1 Regulatory T Cells in Human Chronic Graft-Versus-Host Disease. <i>Journal of Investigative Dermatology</i> , 2021, 141, 193-197.e2.	0.3	4
13	Type I Interferons in Systemic Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment. <i>Frontiers in Pharmacology</i> , 2021, 12, 633821.	1.6	21
14	Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study. <i>Lupus</i> , 2021, 30, 096120332110160.	0.8	7
15	<i>UBA1</i> Variations in Neutrophilic Dermatitis Skin Lesions of Patients With VEXAS Syndrome. <i>JAMA Dermatology</i> , 2021, 157, 1349.	2.0	71
16	DADA2 diagnosed in adulthood versus childhood: A comparative study on 306 patients including a systematic literature review and 12 French cases. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1170-1179.	1.6	14
17	Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series. <i>Frontiers in Immunology</i> , 2021, 12, 715053.	2.2	6
18	Cutaneous drug-induced lupus erythematosus: Clinical and immunological characteristics and update on new associated drugs. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 211-220.	0.5	12

#	ARTICLE	IF	CITATIONS
19	Unusual severe radiation-induced toxicity in a patient with discoid lupus erythematosus: A case report and critical review of the literature. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, , .	0.6	1
20	Antiphospholipid-negative Sneddon's syndrome: A comprehensive overview of a rare entity. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 149, 3-3.	0.5	1
21	Practical management of patients on hydroxychloroquine. <i>Joint Bone Spine</i> , 2021, 88, 105316.	0.8	8
22	Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 317-325.	0.6	52
23	Manifestaciones cutáneas del lupus eritematoso. <i>EMC - Dermatología</i> , 2020, 54, 1-17.	0.1	0
24	Thymoquinone as a causative allergen in <i>Nigella sativa</i> oil contact dermatitis with cross-reactivity to <i>tert-butylhydroquinone</i> . <i>Contact Dermatitis</i> , 2020, 83, 132-134.	0.8	5
25	Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers. <i>Rheumatology</i> , 2020, 59, 3468-3478.	0.9	18
26	Next-Generation Sequencing in Myeloid Neoplasm-Associated Sweet's Syndrome Demonstrates Clonal Relation between Malignant Cells and Skin-Infiltrating Neutrophils. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1873-1876.e5.	0.3	23
27	Clinical and pathological dermatological features of deficiency of adenosine deaminase 2: A multicenter, retrospective, observational study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1794-1798.	0.6	13
28	Discoid drug-induced lupus erythematosus induced by antitumor necrosis factor agents is a very rare subtype of cutaneous lupus: Three cases and literature review. <i>Dermatologic Therapy</i> , 2020, 33, e13364.	0.8	8
29	Belimumab for refractory manifestations of cutaneous lupus: A multicenter, retrospective observational study of 16 patients. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1816-1819.	0.6	19
30	Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. <i>Rheumatology</i> , 2020, 59, 3807-3816.	0.9	24
31	Antipalúdicos de síntesis en dermatología. <i>EMC - Dermatología</i> , 2020, 54, 1-11.	0.1	1
32	Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 504-508.	0.5	54
33	Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation. <i>Haematologica</i> , 2019, 104, e530-e533.	1.7	16
34	Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review. <i>Drugs</i> , 2019, 79, 1199-1215.	4.9	27
35	&p&gt;Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date&p&gt;. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1535-1543.	2.0	47
36	FRI0210...EVALUATION OF THE IMPACT OF ROUTINE MONITORING OF BLOOD HYDROXYCHLOROQUINE LEVELS ON ADHERENCE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	Increased CD8+CD28- circulating T cells and high blood interferon score characterize the systemic inflammation of amyopathic dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2019, 85, 755-758.	0.6	1
38	Cutaneous lupus with Kikuchi disease-like inflammatory pattern associated with myelodysplastic syndrome. <i>Rheumatology</i> , 2019, 58, 554-556.	0.9	1
39	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus "An Ongoing Need for International Consensus and Collaborations. <i>Journal of Investigative Dermatology</i> , 2019, 139, 270-276.	0.3	18
40	Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond. <i>Joint Bone Spine</i> , 2019, 86, 429-436.	0.8	24
41	Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 162-165.	0.6	17
42	Failure of rituximab in refractory erosive lichen planus. <i>British Journal of Dermatology</i> , 2018, 179, 980-981.	1.4	10
43	Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 107-114.e1.	0.6	30
44	Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 342-350.e4.	0.6	52
45	Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1164-1172.	1.3	33
46	Targeting interferons and their pathways in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2018, 17, 44-52.	2.5	107
47	Increased severity and epidermal alterations in persistent versus evanescent skin lesions in adult-onset Still disease. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 969-971.	0.6	18
48	Thromboprophylaxis and thalidomide in the noncancer setting: Toward an algorithm that is based on patient risk factors and underlying disease?. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, e47-e48.	0.6	1
49	Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study. <i>BioMed Research International</i> , 2018, 2018, 1-5.	0.9	11
50	The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. <i>Autoimmunity Reviews</i> , 2018, 17, 781-790.	2.5	59
51	Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2017, 177, 188-196.	1.4	68
52	Dermatopulmonary Syndrome Associated With Anti-MDA5 Antibodies After Allogeneic Hematopoietic Stem Cell Transplantation. <i>JAMA Dermatology</i> , 2017, 153, 184.	2.0	17
53	Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1248-1251.	0.6	27
54	Cutaneous manifestations of Erdheim-Chester disease (ECD): Clinical, pathological, and molecular features in a monocentric series of 40 patients. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 513-520.	0.6	64

#	ARTICLE	IF	CITATIONS
55	The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. Journal of the American Academy of Dermatology, 2016, 74, 693-699.e3.	0.6	59
56	Macular Microangiopathy in Sickle Cell Disease Using Optical Coherence Tomography Angiography. American Journal of Ophthalmology, 2016, 164, 137-144.e1.	1.7	92
57	Influence of smoking on the efficacy of antimalarials in cutaneous lupus: A meta-analysis of the literature. Journal of the American Academy of Dermatology, 2015, 72, 634-639.	0.6	87
58	Erythema multiforme associated with anti-epi-plakin antibodies: a multicentric retrospective case series. Journal of the European Academy of Dermatology and Venereology, 0, , .	1.3	3